The Effect of Solifenacin on Cognitive Function following Stroke

• Main Author: Jin-Woo Park
• Format: Article
• Language: English
• Published: Karger Publishers 2013-05-01
• Series: Dementia and Geriatric Cognitive Disorders Extra
• Subjects: Anticholinergics; Solifenacin; Stroke; Cognitive symptoms; Muscarinic receptors
• Online Access: http://www.karger.com/Article/FullText/350029

Background/Aims: Our aim was to investigate the effect of solifenacin (an anticholinergic) on cognitive function after stroke. Methods: We retrospectively reviewed 66 stroke cases who were prescribed solifenacin for more than 2 months. A control group was generated matching the patients both for sex and age. The interval changes in the Mini-Mental State Examination (MMSE) score and Clinical Dementia Rating Sum of Boxes (CDR-SB) score after solifenacin administration were compared to those of the control group. Results: The baseline MMSE score of the control group was 15.9 ± 9.2 and that of the solifenacin group was 14.3 ± 7.8. After using solifenacin for an average of 76.9 days, there was a change in the MMSE score of 1.9 ± 5.2. During similar periods, there was a change in the MMSE score of 2.9 ± 3.7 in the control group (not using solifenacin). However, there was no significant difference between the two groups. Similarly, there was no significant difference in the CDR-SB score between the two groups. Conclusion: Solifenacin treatment did not affect the short-term cognitive performance in stroke patients. This information might be useful when prescribing anticholinergics to stroke patients.